Stockscreener 앱 받기
12.97
0.08%
-0.010
시간 외 거래:
13.25
0.28
+2.16%
전일 마감가:
$12.98
열려 있는:
$12.95
하루 거래량:
2.22M
Relative Volume:
1.33
시가총액:
$4.08B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-19.06
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
-0.15%
1개월 성능:
+6.22%
6개월 성능:
+55.70%
1년 성능:
+68.01%
1일 변동 폭
$12.66
$13.03
1주일 범위
$12.66
$13.48
52주 변동 폭
$6.685
$13.48
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
12.97 | 4.08B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
124.62 | 55.23B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.01 | 51.37B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.47 | 37.62B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
476.86 | 20.77B | 3.08B | 1.24B | 1.07B | 25.61 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals Files Routine Regulation FD Disclosure Report - TipRanks
Amneal Pharma Expects To Meet Or Exceed Its 2025 Full-Year Financial Guidance - TradingView — Track All Markets
Truist raises PT on Amneal Pharmaceuticals (AMRX) to $15 from $14 - MSN
Is Amneal Pharmaceuticals Inc a strong candidate for buy and holdOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Keiferx collaborates with Amneal on KFRX-06 for Parkinson’s - BioWorld MedTech
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14 - Insider Monkey
How interest rate cuts could boost Amneal Pharmaceuticals Inc. stockJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Nasdaq Moves: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Levels & Weekly Stock Breakout Alerts - Улправда
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsWeekly Investment Recap & Precise Swing Trade Entry Alerts - Улправда
Will Amneal Pharmaceuticals Inc. stock recover faster than peersStability vs Neutral Overview & HOKA model picks for your routine - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock deliver strong dividend growthCushioning Options Review & HOKA model picks for your routine - ulpravda.ru
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance - PharmiWeb.com
A Look At Amneal Pharmaceuticals (AMRX) Valuation As Analyst Optimism And Revenue Outlook Support Recent Momentum - Sahm
KeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.com - Investing.com Canada
KeifeRX announces research collaboration & option agreement with Amneal Pharmaceuticals - MarketScreener
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease - Business Wire
Can Amneal Pharmaceuticals Inc. stock continue upward trendJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - Улправда
Why Amneal Pharmaceuticals Inc. stock remains a top recommendationMarket Risk Summary & Breakout Confirmation Trade Signals - ulpravda.ru
Smart Money: Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Miss & AI Enhanced Market Trend Forecasts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reports2025 Price Momentum & Growth Oriented Trading Recommendations - ulpravda.ru
Is Amneal Pharmaceuticals Inc. stock vulnerable to regulatory risksTrade Risk Summary & Weekly Market Pulse Alerts - ulpravda.ru
What is the fair value of Amneal Pharmaceuticals Inc. stock nowFinancial Sector Performance & Superior Trading Portfolio - ulpravda.ru
Can This Healthcare Stock Keep Going After a Nearly 70% Surge? - Barchart.com
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Raises Target Price to $15 - 富途牛牛
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Unveiling a 10% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com - Investing.com Canada
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Allspring Global Investments Holdings LLC Boosts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
How Recent Q3 Beats And FDA Wins Are Shaping The Amneal Pharmaceuticals (AMRX) Story - Yahoo Finance
Latest FDA Denosumab Decisions Offer Mixed Verdicts - Citeline News & Insights
Suboxone Market is Going to Booming Growth 2025 With Top Key - openPR.com
Amneal Launches Complex Generic Fluorometho-lone Ophthalmic Suspension - Specialty Pharmacy Continuum
Amneal Pharma-mAbxience gets USFDA approval for Boncresa, Oziltus - Medical Dialogues
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.99 - Investing.com
How Amneal Pharmaceuticals Inc. stock trades during market volatilityDividend Yield Trends & Join a Community of Smart Investors - Bollywood Helpline
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Short Squeeze: Why Amneal Pharmaceuticals Inc stock remains a top recommendation2025 Key Highlights & Community Verified Watchlist Alerts - moha.gov.vn
FDA approves Amneal’s two denosumab biosimilars for US market By Investing.com - Investing.com Nigeria
Amneal stock rises after FDA approves two denosumab biosimilars By Investing.com - Investing.com Australia
Amneal Reports FDA Approval of Denosumab Biosimilars - marketscreener.com
Amneal stock rises after FDA approves two denosumab biosimilars - Investing.com
FDA approves Amneal’s two denosumab biosimilars for US market - Investing.com
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - The Manila Times
Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection - Sahm
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.93%
2.43%
자본화:
|
볼륨(24시간):